Belarusian scientists develop universal components and strains of microorganisms to create new drugs

The Institute of Microbiology of the National Academy of Sciences of Belarus has been studying microorganisms for six decades and introducing the knowledge gained into various spheres of the economy. The developments of scientists are used in agriculture, industry, environmental protection, as well as in medicine. About this during the press conference “Pharmindustry of Belarus: innovative methods in the development and implementation of medicines, biotechnology and new quality standards”, timed to the Day of workers of the pharmaceutical and microbiological industry, said the Director of the Institute Alexander Shepshelev.

He added:

The medical field has been developing here for more than 30 years. At the same time, the work of scientists is focused not on the creation of finished drugs, but on the formation of a component base for biopharmaceutics. Specialists develop universal components and strains of microorganisms that can synthesize target molecules and proteins, which are later used in the creation of modern medicines.

According to the head of the institute, biopharmaceutics is one of the most actively developing areas of world science and has significant growth potential. Laboratory technologies are created at the Institute, which can later be scaled and introduced into industrial production. This work is aimed at ensuring the technological sovereignty of the country. Among the achievements of scientists is the development and synthesis of a line of genes for solving specific scientific and practical problems.

The Institute of Microbiology of the NAS is implementing new joint projects, in particular, working on the creation of a non-invasive blood sugar control system. Accumulated knowledge, modern laboratory base and many years of experience allow scientists to solve a wide range of problems on the creation of microorganisms-producers, target proteins and enzymes in demand in various sectors of the economy. From idea to final product: Minskintercaps performs full cycle of drug production